医疗穿戴式註射器市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球医用穿戴注射器市场价值为 17 亿美元，预计到 2034 年将以 15.2% 的复合年增长率成长，达到 66 亿美元。这种快速增长源于多种因素，包括癌症、糖尿病和心血管疾病等慢性病发病率的上升，对家庭医疗保健解决方案的偏好日益增加，以及自我给药系统的加速采用。

穿戴式科技和生物製剂的持续发展进一步推动了市场扩张。这些设备经过专门设计，可穿戴在身上，长时间皮下注射高剂量药物，为患者提供便利，并提高治疗顺从性。它们特别适用于生物製剂和不适合传统注射器或标准自动注射器的高剂量注射剂。市场格局受到日益增长的需求的影响，这些解决方案兼具易用性、精准度和患者舒适度，这使得穿戴式註射器成为现代药物输送方式不可或缺的一部分。

根据设备类型，市场分为可编程穿戴式註射器和非可编程大容量注射器。可程式设备在2024年占据了约74%的市场份额，这得益于其能够提供精准剂量、适应患者特定需求以及支援复杂生物製剂。预计到2034年，该细分市场的规模将超过51亿美元，在分析期间的复合年增长率为15.6%。其先进的功能使其在慢性病管理中尤其具有吸引力，因为持续精准的药物输送至关重要。相较之下，非可编程大容量注射器细分市场预计将以13.8%的复合年增长率增长，这得益于其价格实惠、操作简单以及在大容量给药中越来越多地以预充式和一次性形式使用而受到青睐。

从技术角度来看，市场包括马达驱动、弹簧驱动、膨胀电池驱动、旋转帮浦和其他系统。马达驱动注射器在2024年占据了最大的市场份额，达到31.5%，这得益于其卓越的精度、处理高黏度生物製剂的能力以及与可编程模型的频繁整合。其性能优势在于，无论药物的黏度或体积如何，都能以一致、可控的速率输送药物，这使得它们在慢性病和罕见疾病治疗中使用的复杂药物的给药方面非常有效。

从应用角度来看，肿瘤学在2024年占据40.1%的市场份额，占据领先地位。这个领域占据主导地位的因素包括：全球癌症负担的增加、生物製剂在癌症治疗中的接受度不断提高，以及人们越来越倾向于在家给药以减少对医院的依赖。心血管和自体免疫疾病应用也与肿瘤学一起占据了相当大的市场份额，约占总市场价值的85%。在这些治疗领域，穿戴式针筒兼具便利性和提高患者依从性的双重优势，尤其适用于长期和高剂量的药物治疗方案。

从地区来看，北美占最高份额，2024 年为 51.7%。美国市场在 2021 年达到 12 亿美元，2022 年达到 10 亿美元，随后在 2023 年下降至 9.672 亿美元，2024 年下降至 8.767 亿美元。近期下降主要与主要产品失去独占权有关；然而，排除这一因素，大多数市场参与者仍保持了积极的成长趋势。北美的领先地位得益于其慢性病的高发病率、先进的医疗基础设施以及创新药物输送技术的广泛采用。美国和加拿大拥有大量需要长期治疗的患者，这使得穿戴式註射器对患者和医疗保健提供者来说都是一个有吸引力的解决方案。

为市场成长做出贡献的知名公司包括大型製药和医疗器材製造商，以及专业的药物传输技术公司。这些公司正在积极投资研发，以开发具有增强功能（例如无线连接、更高的药物相容性和用户友好介面）的下一代可穿戴注射器，从而确保市场在未来十年持续扩张。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性病发生率不断上升
    • 转向居家医疗保健
    • 生物製剂需求不断成长
    • 患者对微创设备的偏好
    • 全球人口老化
  • 产业陷阱与挑战
    • 穿戴式註射器成本高
    • 技术和设计挑战
  • 市场机会
    • 生物製剂和大分子药物的成长
    • 居家照护和远端监控的偏好日益增长
• 成长潜力分析
• 监管格局
  • 北美洲
  • 欧洲
• 比较分析：患者对手持式自动注射器与穿戴式大容量注射器的偏好
• 技术进步
  • 当前的技术趋势
  • 新兴技术
  • 技术采用率
• 供应链分析
• 报销场景
  • 穿戴式註射器的成功实施
  • 医疗保健成本降低分析
• 消费者行为趋势
• 产品线分析
• 2024 年全球范围内按设备类型分類的定价分析
• 品牌分析
• 顶尖公司的销售模式
  • 安进
  • 屋宇署
• 顶尖公司的商业模式
  • 安进
  • 屋宇署
  • 其他公司
• 市场进入策略分析
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 差距分析
• 正在开发的生物药物（按治疗类别划分）

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 全球的
  • 北美洲
  • 欧洲
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按设备类型，2021 - 2034 年

• 主要趋势
• 可编程穿戴式註射器
• 不可编程穿戴式註射器

第六章：市场估计与预测：按使用类型，2021 - 2034 年

• 主要趋势
• 免洗可穿戴注射器
• 可重复使用的穿戴式註射器

第七章：市场估计与预测：按技术，2021 - 2034 年

• 主要趋势
• 马达驱动
• 基于 Spring
• 扩充电池
• 旋转泵
• 其他技术

第八章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 肿瘤学
• 心血管疾病
• 自体免疫疾病
• 传染病
• 其他应用

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 世界其他地区

第十章：公司简介

• Amgen
• Becton Dickinson (BD)
• CCBio
• Enable Injections
• Gerresheimer
• LTS Lohmann Therapie-Systeme AG
• Nemera
• Sencoboz
• Stevanato Group
• West Pharmaceutical Services, Inc.
• Ypsomed

The Global Medical Wearable Injector Market was valued at USD 1.7 billion in 2024 and is estimated to grow at a CAGR of 15.2% to reach USD 6.6 billion by 2034. This rapid growth stems from multiple factors, including the increasing incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, a rising preference for home-based healthcare solutions, and the accelerating adoption of self-administered drug delivery systems.

The ongoing advancements in wearable technologies and biologics are further strengthening market expansion. These devices are specifically engineered to administer high-volume medications subcutaneously over extended periods while being worn on the body, offering patients convenience and enabling better treatment adherence. They are particularly suited for biologics and large-volume injectables that are unsuitable for conventional syringes or standard auto-injectors. The market landscape is shaped by the growing demand for solutions that combine ease of use, precision, and patient comfort, making wearable injectors an integral part of modern drug delivery approaches.

By device type, the market is categorized into programmable wearable injectors and non-programmable large volume injectors. Programmable devices represented about 74% of the market share in 2024, driven by their ability to deliver accurate doses, adapt to patient-specific needs, and support complex biologics. This segment is forecasted to exceed USD 5.1 billion by 2034, growing at a CAGR of 15.6% over the analysis period. Their advanced features make them particularly appealing for chronic disease management, where consistent and precise drug delivery is essential. In comparison, the non-programmable large volume injector segment is anticipated to grow at a CAGR of 13.8%, favored for its affordability, simple operation, and increasing use in prefilled, disposable formats for high-volume drug administration.

When assessed by technology, the market includes motor-driven, spring-based, expanding battery, rotary pump, and other systems. Motor-driven injectors accounted for the largest market share at 31.5% in 2024, supported by their superior precision, ability to handle high-viscosity biologics, and frequent integration into programmable models. Their performance advantage lies in delivering drugs at consistent, controlled rates regardless of viscosity or volume, making them highly effective for administering complex medications used in chronic and rare disease therapies.

From an application perspective, oncology led with a 40.1% share in 2024. The segment's dominance is fueled by the rising global cancer burden, increased acceptance of biologics in cancer treatment, and a growing preference for home-based administration options that reduce hospital dependency. Cardiovascular and autoimmune disease applications also hold substantial market shares, together with oncology, representing around 85% of the total market value. Across these therapeutic areas, wearable injectors provide the dual benefits of convenience and improved patient compliance, particularly for long-term and high-volume drug regimens.

Regionally, North America commanded the highest share at 51.7% in 2024. The U.S. market recorded USD 1.2 billion in 2021 and USD 1 billion in 2022 before declining to USD 967.2 million in 2023 and USD 876.7 million in 2024. The recent dip is primarily linked to the loss of exclusivity for a major product; however, excluding this factor, most market players maintained positive growth trends. North America's leading position is reinforced by its high prevalence of chronic diseases, advanced healthcare infrastructure, and strong adoption of innovative drug delivery technologies. The U.S. and Canada together account for a significant patient base requiring long-term treatments, making wearable injectors an attractive solution for both patients and healthcare providers.

Prominent companies contributing to market growth include major pharmaceutical and medical device manufacturers, as well as specialized drug delivery technology firms. These players are actively investing in R&D to develop next-generation wearable injectors with enhanced features such as wireless connectivity, improved drug compatibility, and user-friendly interfaces, ensuring the market's continued expansion over the coming decade.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Device type trends
  • 2.2.3 Usage type trends
  • 2.2.4 Technology trends
  • 2.2.5 Application trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing incidence of chronic conditions
    • 3.2.1.2 Shift towards home-based healthcare
    • 3.2.1.3 Increasing demand for biologics
    • 3.2.1.4 Patient preference for minimally invasive devices
    • 3.2.1.5 Global aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of wearable injectors
    • 3.2.2.2 Technical and design challenges
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growth in biologics and large-molecule drugs
    • 3.2.3.2 Rising preference for at-home care & remote monitoring
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
• 3.5 Comparative analysis: Patient preferences for handheld autoinjectors Vs wearable large-volume injectors
• 3.6 Technological advancements
  • 3.6.1 Current technological trends
  • 3.6.2 Emerging technologies
  • 3.6.3 Technology adoption rate
• 3.7 Supply chain analysis
• 3.8 Reimbursement scenario
  • 3.8.1 Successful implementation of wearable injectors
  • 3.8.2 Healthcare cost reduction analysis
• 3.9 Consumer behaviour trend
• 3.10 Product pipeline analysis
• 3.11 Pricing analysis, by device type, at global level, 2024
• 3.12 Brand analysis
• 3.13 Sales model of top companies
  • 3.13.1 Amgen
  • 3.13.2 BD
• 3.14 Business model of top companies
  • 3.14.1 Amgen
  • 3.14.2 BD
  • 3.14.3 Other companies
• 3.15 Go-to-market strategy analysis
• 3.16 Porter's analysis
• 3.17 PESTEL analysis
• 3.18 Future market trends
• 3.19 Gap analysis
• 3.20 Biologic medicines in development, by therapeutic categories

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Device Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Programmable wearable injectors
• 5.3 Non-programmable wearable injectors

Chapter 6 Market Estimates and Forecast, By Usage Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Disposable wearable injectors
• 6.3 Reusable wearable injectors

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Motor-driven
• 7.3 Spring-based
• 7.4 Expanding battery
• 7.5 Rotary pump
• 7.6 Other technologies

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Cardiovascular disease
• 8.4 Autoimmune disease
• 8.5 Infectious disease
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Rest of World

Chapter 10 Company Profiles

• 10.1 Amgen
• 10.2 Becton Dickinson (BD)
• 10.3 CCBio
• 10.4 Enable Injections
• 10.5 Gerresheimer
• 10.6 LTS Lohmann Therapie-Systeme AG
• 10.7 Nemera
• 10.8 Sencoboz
• 10.9 Stevanato Group
• 10.10 West Pharmaceutical Services, Inc.
• 10.11 Ypsomed